gilead glp-1 trims assets partnered with Novo Nordisk, Arcus from pipeline 1 medications or looking to feel their best every day. Gilead Sciences describes new GLP-1R

For many, the battle against weight is as much mental as it is physical

This article reviews the glucagon-like peptide 1 (GLP-1) agonistbased therapies as a new class of antidiabetic and their potential effects beyond glucose control that may ultimately impact cardiovascular disease

This observation led to a study where GLP-1 was given to obese patients with T2DM and showed improved glycemic control with no side effects, establishing a proof-of-concept for GLP-1 agonists, which over time led to their use in the treatment of T2DM patients [21]

We partner with you every step of the way, providing the support, education, and medical expertise that other telehealth providers leave out

Remember: medication is just one tool

Retrieved from Jensen, T